Screening with a high-precision blood-based assay for Alzheimer disease

Affiliations

¹ From the Wisconsin Alzheimer's Disease Research Center (B.B.B.), University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison; Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry (H.Z.), Sahlgrenska Academy at University of Gothenburg; Clinical Neurochemistry Laboratory (H.Z.), Sahlgrenska University Hospital, Mölndal, Sweden; Department of Neurodegenerative Disease (H.Z.), University College London Institute of Neurology; and UK Dementia Research Institute at UCL (H.Z.), London, UK. bbb@medicine.wisc.edu.
² From the Wisconsin Alzheimer's Disease Research Center (B.B.B.), University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison; Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry (H.Z.), Sahlgrenska Academy at University of Gothenburg; Clinical Neurochemistry Laboratory (H.Z.), Sahlgrenska University Hospital, Mölndal, Sweden; Department of Neurodegenerative Disease (H.Z.), University College London Institute of Neurology; and UK Dementia Research Institute at UCL (H.Z.), London, UK.

Editorial

Barbara B Bendlin et al. Neurology. 2019.

. 2019 Oct 22;93(17):737-738.

doi: 10.1212/WNL.0000000000008080. Epub 2019 Aug 1.

¹ From the Wisconsin Alzheimer's Disease Research Center (B.B.B.), University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison; Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry (H.Z.), Sahlgrenska Academy at University of Gothenburg; Clinical Neurochemistry Laboratory (H.Z.), Sahlgrenska University Hospital, Mölndal, Sweden; Department of Neurodegenerative Disease (H.Z.), University College London Institute of Neurology; and UK Dementia Research Institute at UCL (H.Z.), London, UK. bbb@medicine.wisc.edu.
² From the Wisconsin Alzheimer's Disease Research Center (B.B.B.), University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison; Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry (H.Z.), Sahlgrenska Academy at University of Gothenburg; Clinical Neurochemistry Laboratory (H.Z.), Sahlgrenska University Hospital, Mölndal, Sweden; Department of Neurodegenerative Disease (H.Z.), University College London Institute of Neurology; and UK Dementia Research Institute at UCL (H.Z.), London, UK.

No abstract available

Comment on

High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis.
Schindler SE, Bollinger JG, Ovod V, Mawuenyega KG, Li Y, Gordon BA, Holtzman DM, Morris JC, Benzinger TLS, Xiong C, Fagan AM, Bateman RJ. Schindler SE, et al. Neurology. 2019 Oct 22;93(17):e1647-e1659. doi: 10.1212/WNL.0000000000008081. Epub 2019 Aug 1. Neurology. 2019. PMID: 31371569 Free PMC article.